AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT
Exhibit 10.1
AMENDMENT NO. 2 TO
THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment”) made as of May 24, 2012 (“Effective Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Xxxxxx X. Xxxxx, Ph.D. (“Employee”).
| 1. | This Amendment No. 2 is intended to amend and modify that certain Amended and Restated Employment Agreement by and between the Company and Employee dated January 1, 2009 and amended on May 8, 2012 (the “Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in the Agreement. Except as expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. |
| 2. | The defined term “Termination Compensation,” as provided in Section 7(c) of the Agreement, is hereby deleted and replaced in its entirety by the following definition: |
Termination Compensation. For purposes of this Agreement, the term “Termination Compensation” shall mean: (i) one hundred fifty percent (150%) of the Employee’s then current annual base salary which shall be payable in a lump sum within two weeks after separation of employment, conditioned on Employee executing the Company’s standard form severance and release agreement, and shall be subject to customary withholding and other applicable payroll processes. Employee shall execute the Company’s standard form severance and release agreement within sixty (60) days after the Employee’s termination.
| 3. | This Amendment No. 2 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. |
IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the date first written above.
|
|
EMPLOYEE
| |||||||
| By: | /s/Xxxx-Xxxxxxx Xxxxxxxx |
By: | /s/ Xxxxxx X. Xxxxx | |||||
| Name: | Xxxx-Xxxxxxx Xxxxxxxx | Xxxxxx X. Xxxxx, Ph.D. | ||||||
| Its: | Chief Executive Officer | |||||||
